The growing number of clinical trials testing neoadjuvant immunotherapy with or without chemotherapy has opened up new possibilities for treating locally advanced solid tumors.
The proliferation of preoperative neoadjuvant trials with immune-oncology (IO) alone or IO plus chemotherapy has led to a consistent wave of opportunities in locally advanced disease in the upfront setting across many solid tumors. At the European Society for Medical Oncology (ESMO) Congress 2023, Tina Cascone, MD, and colleagues1 presented data from a late-breaking abstract about the benefit of adding the PD-1 inhibitor nivolumab (Opdivo) to chemotherapy for patients with stage II to IIIB non–small cell lung cancer or head and neck cancer, as well as other solid tumors. We are seeing a greater application of these neoadjuvant approaches and combinations of IO-IO, IO plus chemotherapy, and sometimes IO with stereotactic radiation, leading to substantial tumor reductions and, in some cases, deep or complete responses.
In the past, the effort to identify biomarkers of response was one of the goals of these trials, whereas now the responses are deep and durable enough to permit alterations in clinical decision-making. Organ preservation and reduced extent of surgical resection are potential dramatic benefits, coupled with the prospect of immune memory, leading to reduction in tumor, recurrence, and subsequently improved overall survival. It appears that inflamed tumors at baseline, as well as those with high expression of the ligand PD-L1, may be affected most; selecting those patients who would benefit from neoadjuvant therapy is one of the frontiers for application of this type of therapy.
Neoadjuvant therapy shows great benefits, such as improved overall survival and quality of life, for patients with early-stage disease when cancer-involved organs can be salvaged, be preserved by stimulating immunity and restoring function, or not be surgically removed. Eliciting the appropriate and most effective combinations, such as doublet IO or chemotherapy combinations, is under investigation, as well as which situations would warrant postoperative continuation of the immunotherapeutic agents. This is a tremendously exciting time in locally advanced disease because a brief neoadjuvant course of IO therapy may not only demonstrate immediate benefits, but in responders, it has shown progression-free and potentially overall survival benefits.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More